^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Imjudo (tremelimumab-actl)

    i
    Other names: CP-675206, CP-675,206, CP-675, PF-06753388, CP 675, CP675, PF 06753388, PF06753388, CP675206, CP 675206
    Company:
    AstraZeneca, Pfizer
    Drug class:
    CTLA4 inhibitor
    Related drugs:
    2d
    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MSH6 (MutS homolog 6)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    3d
    CCTG BR34: Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC (clinicaltrials.gov)
    P2, N=301, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
    |
    EGFR mutation • ALK fusion
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    4d
    MYSTIC: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=1118, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • paclitaxel • Imjudo (tremelimumab-actl) • pemetrexed
    7d
    Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights. (PubMed, Anticancer Res)
    A history of Ate/Bev therapy increased soluble MHC class I and sPD-L1 serum levels. Tre/Dur therapy may be useful as a first-line treatment for uHCC, and elevated sPD-L1 levels may attenuate Dur efficacy. This increase may impair tumor recognition and potentially reduce Tre/Dur therapy effectiveness despite activated cytotoxic T cells.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2RA (Interleukin 2 receptor, alpha)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    8d
    Effective Treatment of Advanced Hepatocellular Carcinoma with Extensive Peritoneal Dissemination Using Lenvatinib. (PubMed, Acta Med Okayama)
    Combined immunotherapy with durvalumab/tremelimumab was initiated;however, disease progression was observed after three treatment courses, prompting a switch to lenvatinib therapy. Thirteen months after switching to lenvatinib (16 months after the initial diagnosis), the alpha-fetoprotein level continued to decrease, and the disease remained stable under treatment. Despite the extremely high tumor burden, lenvatinib achieved disease stabilization and symptomatic improvement.
    Journal
    |
    AFP (Alpha-fetoprotein)
    |
    Imfinzi (durvalumab) • Lenvima (lenvatinib) • Imjudo (tremelimumab-actl)
    11d
    Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass). (PubMed, Ther Adv Med Oncol)
    The MONTBLANC study aims at guiding the design of future trials in aHCC by assessing efficacy signals of upfront triple or response-adapted treatment escalation with durvalumab, tremelimumab, and bevacizumab. The MONTBLANC clinical trial is registered at the US National Institutes of Health (ClinicalTrials.gov, NCT05844046) and the European Union Drug Regulating Authorities Clinical Trials Database (clinicaltrialsregister.eu, 2022-001201-48).
    Journal
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    15d
    BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Case Comprehensive Cancer Center | N=43 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • First-in-human
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    16d
    IMMUWIN: Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC (clinicaltrials.gov)
    P2, N=55, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    17d
    SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P3, N=111, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Sep 2026
    Trial completion date
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    17d
    D7029C00001: Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcinoma (2024-518210-81-00)
    P2/3, N=273, Not yet recruiting, AstraZeneca AB
    New P2/3 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)
    22d
    Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (clinicaltrials.gov)
    P3, N=953, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 negative
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • paclitaxel • Imjudo (tremelimumab-actl) • pemetrexed
    25d
    CHESS: Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, ETOP IBCSG Partners Foundation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)